The results of the review were as follows:
1. Drug of choice utilisation rates:
a. The use of beta agonists after myocardial infarction was 100% intervention, and 50% control;
b. The use of ACE inhibitors in diabetics with proteinuria was 100% intervention, and 50% control;
c. The use of ACE inhibitors in asymptomatic left ventricular dysfunction was 100% intervention, and 50% control.
2. Annual probability of complications from the pre-morbid state:
a. The probability of a repeat myocardial infarction was 0.048 in patients receiving the drug of choice (beta-antagonists), and 0.067 in patients receiving an alternative drug;
b. The probability of developing end stage renal disease for diabetic patients with proteinuria, treated with the drug of choice (ACE inhibitors) was 0.032, and 0.051 in patients receiving an alternative drug;
c. The probability of patients with asymptomatic left ventricular function developing congestive heart failure was 0.069 for patients treated with the drug of choice (ACE inhibitors), and 0.101 for patients receiving an alternative drug.
3. Annual probabilities of death from the pre-morbid state:
a. The probability of death after first myocardial infarction was 0.035 in patients receiving the drug of choice (beta-antagonists), and 0.054 in patients receiving an alternative drug;
b. The probability of death in diabetic patients with proteinuria was 0.013 in patients receiving the drug of choice (ACE-inhibitors), and 0.023 in patients receiving an alternative drug;
c. The probability of death in patients with left ventricular dysfunction was 0.049 in patients receiving the drug of choice (ACE-inhibitors), and 0.053 in patients receiving an alternative drug.
4. Annual probabilities of death from the complication state:
a. The probability of death from a second myocardial infarction was 0.11;
b. The probability of death in diabetic patients receiving haemodialysis was 0.13;
c. The probability of death in patients with established congestive heart failure was 0.088.